You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 117 No. 6, JUNE 1966 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (6)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Fibrinolysis and Proteolysis in Patients With Lymphoma

ANTONIO GIROLAMI, MD; EUGENE E. CLIFFTON, MD

Arch Intern Med. 1966;117(6):778-783.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

INCREASED fibrinolytic activity has been described in several malignant diseases. Acute and chronic leukemia 1-9 and metastatic carcinoma of the prostate 10-14 are the conditions most commonly reported to be associated with marked fibrinolysis. Hyperfibrinolysis has also been observed in polycythemia vera,15 multiple myeloma,14,16 carcinoma of the pancreas,17 metastatic carcinoma of the stomach,18 and neuroblastoma.19

The behavior of blood fibrinolysis in lymphomas is still poorly known. Increased in vitro fibrinogenolysis has been demonstrated in the plasma of ten out of 11 patients with Hodgkin's disease.20 Others 4,18,21 found the fibrinolytic activity to be practically normal in patients with lymphomas showing only occasional minor inhibition 21 or acceleration.18

The present investigation reports our observations of fibrinolysis and proteolysis in a series of 125 patients with Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma.

Materials and Methods

Of the 125 patients, 58 had Hodgkin's disease, 33 had lymphosarcoma, and 34 had reticulum cell . . . [Full Text PDF of this Article]


Author Affiliations

NEW YORK

From the Clotting Mechanisms Section, Memorial Sloan-Kettering Cancer Center, New York. Dr. Girolami is presently at the Institute of Semeiotica Medica, University of Padua Medical School, Padua, Italy.


Footnotes

Received for publication Dec 28, 1965; accepted Jan 28, 1966.

Reprint requests to Memorial Sloan-Kettering Cancer Center, New York, NY (Dr. Clifton).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1966 American Medical Association. All Rights Reserved.